# Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

> **NCT02631044** · PHASE1 · COMPLETED · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 387 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle-cell Lymphoma
- Primary Mediastinal B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** JCAR017 (lisocabtagene maraleucel) single-dose schedule
- **BIOLOGICAL:** JCAR017 (lisocabtagene maraleucel) 2-dose schedule

## Key facts

- **NCT ID:** NCT02631044
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-06
- **Primary completion:** 2024-05-16
- **Final completion:** 2024-05-16
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631044, "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02631044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*